Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03246854
Recruitment Status : Recruiting
First Posted : August 11, 2017
Last Update Posted : September 28, 2018
Sponsor:
Information provided by (Responsible Party):
National Health Research Institutes, Taiwan

Brief Summary:
The study is being performed to assess the MTD, pharmacokinetics (PK), safety, tolerability and preliminary antitumor activity of DBPR112 in patients with head and neck cancer and EGFR mutated lung cancer.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer NSCLC Drug: DBPR112 Phase 1

Detailed Description:
This is a Phase I, multi-center, open-label, first-in-human study to determine the MTD and RP2D of DBPR112 and to assess the safety, tolerability and PK of DBPR112 in Asian patients. Patients with non-small cell cancer (NSCLC) who have progressed following prior therapy with an epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor or in patients with squamous cell cancer of head and neck (SCCHN) who have progressed following prior standard therapy will be selected. Approximately 24 to 30 patients will be enrolled in this study as out patients/inpatients, in 2 study centers in Taiwan.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I, Open-Label, Multiple Dose, Dose-Finding and Expansion Clinical Study to Assess the Safety, Pharmacokinetics, and Efficacy of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer
Actual Study Start Date : July 18, 2017
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : May 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: DBPR112 Drug: DBPR112
DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.




Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) [ Time Frame: up to 22 months ]
  2. Area Under the Plasma Concentration-Time Curve (AUC from 0 to infinity) [ Time Frame: For Cycle 1 (each cycle is 28 days) and Cycle 2, Day 1, predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8 and 24 hrs (i.e. predose on Day 2).Predose samples on Cycle 1 Days 8, 15, 22, and 28, Cycle 2 Day 15, and Cycle3-6 Days 1 and 15. ]
  3. Observed Maximum Plasma Concentration (Cmax) [ Time Frame: For Cycle 1 (each cycle is 28 days) and Cycle 2, Day 1, predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8 and 24 hrs (i.e. predose on Day 2).Predose samples on Cycle 1 Days 8, 15, 22, and 28, Cycle 2 Day 15, and Cycle3-6 Days 1 and 15. ]
  4. Time of Maximum Plasma Concentration (tmax) [ Time Frame: For Cycle 1 (each cycle is 28 days) and Cycle 2, Day 1, predose (0 hr), 0.5, 1, 2, 3, 4, 6, 8 and 24 hrs (i.e. predose on Day 2).Predose samples on Cycle 1 Days 8, 15, 22, and 28, Cycle 2 Day 15, and Cycle3-6 Days 1 and 15. ]

Secondary Outcome Measures :
  1. Incidence and intensity of Adverse Events and Serious Adverse Events as a measure of safety [ Time Frame: Adverse events were collected from the time of the first dose of investigational product until 30 days after the last dose of investigational product administration. ]
  2. Preliminary antitumor activity of DBPR112 in patients with solid tumors [ Time Frame: The tumor responses were collected from the time of the first dose of investigational product until 30 days after the last dose of investigational product administration. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients
  • Age from ≥18 to ≤70 years
  • Life expectancy >12 weeks per investigator's judgement
  • Squamous cell carcinoma of head and neck that has failed prior standard therapy for metastatic disease or advanced EGFR-mutated NSCLC that has failed prior standard therapy including at least one anti EGFR TK inhibitor
  • Non-measurable but evaluable disease, or measurable disease per RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate blood and organ function
  • Male and female patients must agree to use contraception while on study and for 90 days after the last dose of DBPR112
  • Aspartate aminotransferase/ALT <3 X ULN if no metastasis, and AST/ALT <5 X ULN in presence of metastasis

Exclusion Criteria:

  • History of allergic reactions to any component of DBPR112
  • History of unstable central nervous system (CNS) metastases or seizure disorder related to the malignancy; however, those patients who were treated for prior CNS metastases and who are asymptomatic may participate in the study
  • History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, or cardiac arrhythmia
  • Exposure to any other investigational or commercial anticancer agents or therapies administered with the intention to treat malignancy within 28 days for chemotherapeutics and targeted agents, or 5 half-lives for proteins, whichever is longer, before the first dose of DBPR112
  • Significant surgical intervention within 21 days of the first dose of DBPR112 or with ongoing postoperative complications
  • Chronic skin condition that requires prescribed oral or intravenous treatment
  • History of severe rash that required discontinuation of prior EGFR targeted therapy
  • History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapy
  • Toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade 0 or 1 as per the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 or equivalent
  • Insufficient organ function as indicated by the following parameters

    1. Absolute neutrophil count (ANC) <1,500 /µL
    2. Platelets <100,000 /µL
    3. Hemoglobin <10 g/dL
    4. Serum creatinine >1.5 X ULN
    5. Serum total bilirubin >1.5 X ULN
    6. Aspartate aminotransferase/ALT >3 X ULN if no metastasis, AST/ALT >5 X ULN in presence of metastasis
    7. International normalized ratio or prothrombin time >1.5 X ULN
  • Known history of human immunodeficiency virus (HIV)1 or 2
  • Active clinically significant infection requiring systemic therapy
  • Positive test for hepatitis B (HBsAg) or hepatitis C (anti-HCV antibody)
  • Child-Pugh B & C stage liver disease or liver function impairment
  • Underlying medical conditions that, in the Investigator's opinion, will make the administration of DBPR112 hazardous or obscure the interpretation of toxicity or AEs
  • Inability to swallow oral medications (capsules and tablets) without chewing, breaking, crushing, opening or otherwise altering the product formulation. Patients should not have gastrointestinal illnesses that would preclude the absorption of DBPR112, which is an oral agent
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements
  • Pregnancy or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03246854


Contacts
Layout table for location contacts
Contact: Chia-Chi Lin, M.D., Ph.D. 886-2-2312-3456 ext 67680 cclin1@ntu.edu.tw

Locations
Layout table for location information
Taiwan
National Taiwan University Hospital Not yet recruiting
Taipei, Taiwan, 10048
Contact: Chia-Chi Lin, M.D., Ph.D.         
Taipei Medical University Hospital Recruiting
Taipei, Taiwan, 110
Contact: Her-Shyong Shiah, M.D.         
Sponsors and Collaborators
National Health Research Institutes, Taiwan

Layout table for additonal information
Responsible Party: National Health Research Institutes, Taiwan
ClinicalTrials.gov Identifier: NCT03246854     History of Changes
Other Study ID Numbers: DBPR112-101
First Posted: August 11, 2017    Key Record Dates
Last Update Posted: September 28, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Health Research Institutes, Taiwan:
DBPR112
EGFR mutated NSCLC
squamous cell cancer of head and neck
maximum tolerated dose
recommended Phase 2 dose

Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms